Drug Patent Watch

OCTOBER 31, 2019

The launch of a new product can be a daunting task. The main reason this happens is that no matter how many times your company has managed to enter new…. The post Mistakes to Be Avoided When Preparing a Drug Launch appeared first on DrugPatentWatch - Make Better Decisions.

63

63

RxNotes

OCTOBER 26, 2019

Drug names, whether brand or generic, are sometimes a pharmacist’s worst enemy. Pronunciation struggles, spelling difficulties, and memorization issues make you wonder how and why pharmaceutical companies come to name their drugs. This is how I assumed drug names were created, but Twitter user Andy Webb (@AJWPharm) started a great thread on drug origin names.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

OCTOBER 30, 2019

Overview Oncology treatment increasingly involves combinations of novel oral and biologic drugs. While combo approaches aren’t new, there are significant cost implications of combining high priced innovator drugs (versus older, generic chemotherapies). Payers are in a difficult spot regarding the cost and management of these regimens. Traditional utilization management tools are still difficult to apply in oncology, given no payer wants to be on the front page of a major newspaper for denying tr

Chemotherapy 40

Chemotherapy 40

Med Ed 101

OCTOBER 30, 2019

In this case scenario below, I discuss the mirabegron tamoxifen interaction and how it can impact patient safety. KS is a 61-year-old female who presents with worsening urinary frequency. She has been diagnosed with overactive bladder and place on oxybutynin. She was taking 5 mg daily and states that the dry mouth from the medication […]. The post Mirabegron Tamoxifen Interaction – Case Scenario appeared first on Med Ed 101.

40

40

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Drug Patent Watch

OCTOBER 29, 2019

This article was originally published by Garth Boehm, Lixin Yao, Liang Hana, and Qiang Zheng in Acta Pharmaceutica Sinica under a creative commons license. Abstract The key events in the…. The post Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984 appeared first on DrugPatentWatch - Make Better Decisions.

53

53